STRUCTURE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.23 USD | -1.43% |
|
-6.92% | -8.66% |
| Jun. 27 | Structure Therapeutics Inc. Appoints Ted W. Love as to the Audit Committee | CI |
| Jun. 07 | Structure Therapeutics Closes $547.4 Million Offering | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,991 | 1,736 | - | - |
| Enterprise Value (EV) 1 | 1,991 | 1,400 | 1,580 | 1,448 |
| P/E ratio | -50.3 x | -40.5 x | -46.1 x | -23.3 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 31.2 x | - |
| EV / Revenue | - | - | 28.4 x | - |
| EV / EBITDA | - | -8.62 x | -8.75 x | -6.64 x |
| EV / FCF | -24.4 x | -7.53 x | -8.68 x | -6.06 x |
| FCF Yield | -4.1% | -13.3% | -11.5% | -16.5% |
| Price to Book | - | 5.64 x | 12.5 x | 4.46 x |
| Nbr of stocks (in thousands) | 48,855 | 46,621 | - | - |
| Reference price 2 | 40.76 | 37.23 | 37.23 | 37.23 |
| Announcement Date | 3/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 55.56 | - |
| EBITDA 1 | - | - | - | -162.4 | -180.6 | -217.9 |
| EBIT 1 | - | -52.56 | -102.8 | -156.2 | -211.8 | -258.5 |
| Operating Margin | - | - | - | - | -381.25% | - |
| Earnings before Tax (EBT) 1 | - | -51.3 | -89.38 | -144.9 | -197.7 | -240 |
| Net income 1 | -38.05 | -52.84 | -89.62 | -132.4 | -122.7 | -226 |
| Net margin | - | - | - | - | -220.93% | - |
| EPS 2 | -5.380 | -5.510 | -0.8100 | -0.9200 | -0.8071 | -1.598 |
| Free Cash Flow 1 | - | -46.28 | -81.66 | -186 | -182 | -239 |
| FCF margin | - | - | - | - | -327.6% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/12/23 | 3/30/23 | 3/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | -32 | -47 | -52 | - | - |
| EBIT 1 | -12.96 | -19.65 | -25.99 | -26.14 | -30.99 | -32.02 | -35.88 | -41.59 | -50.65 | -40.84 | -43.4 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.06 | -17.95 | -23.16 | -23.46 | -24.82 | -26.01 | -33.03 | -39.27 | -44.09 | -40.84 | -43.4 |
| Net income 1 | -11.88 | -17.98 | -23.28 | -23.86 | -24.5 | -26.04 | -32.19 | -36.84 | -40.89 | -40.84 | -43.4 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.170 | -0.2500 | -0.2000 | -0.2100 | -0.1600 | -0.1900 | -0.2271 | -0.2400 | -0.2600 | -0.2600 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/8/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 336 | 156 | 288 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -46.3 | -81.7 | -186 | -182 | -239 |
| ROE (net income / shareholders' equity) | - | - | - | -41.5% | -81.5% | -75.8% |
| ROA (Net income/ Total Assets) | - | - | - | -37.8% | -67.3% | -64% |
| Assets 1 | - | - | - | 350.3 | 182.3 | 353.4 |
| Book Value Per Share 2 | - | - | - | 6.600 | 2.990 | 8.340 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 3 | 1.5 | 1.5 |
| Capex / Sales | - | - | - | - | 2.7% | - |
| Announcement Date | 1/12/23 | 3/30/23 | 3/8/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.23
USD
Average target price
83.1
USD
Spread / Average Target
+123.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.66% | 1.74B | |
| +18.43% | 124B | |
| +19.81% | 114B | |
| -23.74% | 19.42B | |
| -18.14% | 16.2B | |
| -19.97% | 15.31B | |
| -49.33% | 14.19B | |
| +57.08% | 14.32B | |
| +7.95% | 14.31B | |
| +126.04% | 11.29B |
- Stock Market
- Equities
- GPCR Stock
- Financials Structure Therapeutics Inc.
